AIMS: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRD1-DRD5, AKT1 and GSK3beta) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia. MATERIALS & METHODS: A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale. RESULTS: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone. CONCLUSION: These data suggest that the SNPs in DRD2 and AKT1 may influence the treatment response to risperidone in schizophrenia patients.
AIMS: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRD1-DRD5, AKT1 and GSK3beta) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia. MATERIALS & METHODS: A total of 120 first-episode neuroleptic-naive schizophreniapatients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale. RESULTS: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone. CONCLUSION: These data suggest that the SNPs in DRD2 and AKT1 may influence the treatment response to risperidone in schizophreniapatients.
Authors: Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2011-06 Impact factor: 2.089
Authors: Aaron Jenkins; José A Apud; Fengyu Zhang; Heather Decot; Daniel R Weinberger; Amanda J Law Journal: Neuropsychopharmacology Date: 2014-03-14 Impact factor: 7.853
Authors: Ajna Hamidovic; Andrea Dlugos; Andrew Skol; Abraham A Palmer; Harriet de Wit Journal: Exp Clin Psychopharmacol Date: 2009-12 Impact factor: 3.157
Authors: Q Xu; X Wu; M Li; H Huang; C Minica; Z Yi; G Wang; L Shen; Q Xing; Y Shi; L He; S Qin Journal: Pharmacogenomics J Date: 2015-08-18 Impact factor: 3.550
Authors: Willard M Freeman; Melinda E Lull; Kruti M Patel; Robert M Brucklacher; Drake Morgan; David C S Roberts; Kent E Vrana Journal: BMC Neurosci Date: 2010-02-26 Impact factor: 3.288